Assessment of the population coverage of an HIV-1 vaccine targeting sequences surrounding the viral protease cleavage sites in Gag, Pol, or all 12 protease cleavage sites

Daniel, Mathew; Liang, Binhua; Luo, Ma

doi:10.1016/j.vaccine.2021.03.068

Cited by 3 publications

(3 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our studies also showed that many HLA class I alleles common among distinct populations worldwide, restrict validated epitopes surrounding multiple PCSs [73,83]. Based on the validated CD8 T cell epitopes surrounding the HIV PCSs, an HIV vaccine targeting sequences surrounding the PCSs can cover 97.8% of the world's population with average epitope hits of 13.68 [83]. The population coverage and average epitope hits are very high for North American (98.36%, 14.26), European (99.12%, 15.82), African (South (95.53%, 7.77), East (96.60%, 8.73), West (94.13%, 9.14), Central (93.70%, 7.76) and North (95.11%, 9.33)), and Asian (>90%, ~10.1) populations [83].…”

Section: From Hla Epitope Analysis To Novel Hiv Vaccine Development A...supporting

confidence: 58%

“…Thus, a vaccine focusing immune responses on sequences surrounding these sites should be effective across multiple HIV subtypes. Our studies also showed that many HLA class I alleles common among distinct populations worldwide, restrict validated epitopes surrounding multiple PCSs [73,83]. Based on the validated CD8 T cell epitopes surrounding the HIV PCSs, an HIV vaccine targeting sequences surrounding the PCSs can cover 97.8% of the world's population with average epitope hits of 13.68 [83].…”

Section: From Hla Epitope Analysis To Novel Hiv Vaccine Development A...mentioning

confidence: 61%

“…Based on the validated CD8 T cell epitopes surrounding the HIV PCSs, an HIV vaccine targeting sequences surrounding the PCSs can cover 97.8% of the world's population with average epitope hits of 13.68 [83]. The population coverage and average epitope hits are very high for North American (98.36%, 14.26), European (99.12%, 15.82), African (South (95.53%, 7.77), East (96.60%, 8.73), West (94.13%, 9.14), Central (93.70%, 7.76) and North (95.11%, 9.33)), and Asian (>90%, ~10.1) populations [83]. Therefore, a vaccine targeting sequences surrounding the 12 PCSs can potentially generate CD8 T cell responses to eight or all the PCSs in a given individual.…”

Section: From Hla Epitope Analysis To Novel Hiv Vaccine Development A...mentioning

confidence: 99%

See 2 more Smart Citations

Natural Immunity against HIV-1: Progression of Understanding after Association Studies

Luo

2022

Viruses

Self Cite

View full text Add to dashboard Cite

Natural immunity against HIV has been observed in many individuals in the world. Among them, a group of female sex workers enrolled in the Pumwani sex worker cohort remained HIV uninfected for more than 30 years despite high-risk sex work. Many studies have been carried out to understand this natural immunity to HIV in the hope to develop effective vaccines and preventions. This review focuses on two such examples. These studies started from identifying immunogenetic or genetic associations with resistance to HIV acquisition, and followed up with an in-depth investigation to understand the biological relevance of the correlations of protection, and to develop and test novel vaccines and preventions.

show abstract

Section: From Hla Epitope Analysis To Novel Hiv Vaccine Development A...supporting

confidence: 58%

Section: From Hla Epitope Analysis To Novel Hiv Vaccine Development A...mentioning

confidence: 61%

Section: From Hla Epitope Analysis To Novel Hiv Vaccine Development A...mentioning

confidence: 99%

See 1 more Smart Citation

Natural Immunity against HIV-1: Progression of Understanding after Association Studies

Luo

2022

Viruses

Self Cite

View full text Add to dashboard Cite

show abstract

A long-term stable cold-chain-friendly HIV mRNA vaccine encoding multi-epitope viral protease cleavage site immunogens inducing immunogen-specific protective T cell immunity

Mandal,

Ghosh,

Lohani

et al. 2024

Emerging Microbes & Infections

View full text Add to dashboard Cite

Reverse vaccinology approaches to design a potent multiepitope vaccine against the HIV whole genome: immunoinformatic, bioinformatics, and molecular dynamics approaches

Hashempour,

Khodadad,

Akbarinia

et al. 2024

BMC Infect Dis

View full text Add to dashboard Cite

Substantial advances have been made in the development of promising HIV vaccines to eliminate HIV-1 infection. For the first time, one hundred of the most submitted HIV subtypes and CRFs were retrieved from the LANL database, and the consensus sequences of the eleven HIV proteins were obtained to design vaccines for human and mouse hosts. By using various servers and filters, highly qualified B-cell epitopes, as well as HTL and CD8 + epitopes that were common between mouse and human alleles and were also located in the conserved domains of HIV proteins, were considered in the vaccine constructs. With 90% coverage worldwide, the human vaccine model covers a diverse allelic population, making it widely available. Codon optimization and in silico cloning in prokaryotic and eukaryotic vectors guarantee high expression of the vaccine models in human and E. coli hosts. Molecular dynamics confirmed the stable interaction of the vaccine constructs with TLR3, TLR4, and TLR9, leading to a substantial immunogenic response to the designed vaccine. Vaccine models effectively target the humoral and cellular immune systems in humans and mice; however, experimental validation is needed to confirm these findings in silico.

show abstract

Assessment of the population coverage of an HIV-1 vaccine targeting sequences surrounding the viral protease cleavage sites in Gag, Pol, or all 12 protease cleavage sites

Cited by 3 publications

References 20 publications

Natural Immunity against HIV-1: Progression of Understanding after Association Studies

Natural Immunity against HIV-1: Progression of Understanding after Association Studies

A long-term stable cold-chain-friendly HIV mRNA vaccine encoding multi-epitope viral protease cleavage site immunogens inducing immunogen-specific protective T cell immunity

Reverse vaccinology approaches to design a potent multiepitope vaccine against the HIV whole genome: immunoinformatic, bioinformatics, and molecular dynamics approaches

Contact Info

Product

Resources

About